irinotecan/floxuridine (CPX-1) / Jazz - LARVOL DELTA

Cemiplimab FDA Approval Application for Recurrent or Metastatic Cervical Cancer Withdrawn (Targeted Oncology) - "'This is a randomized phase 3 trial [conducted] internationally [to evaluate] cemiplimab 350 mg every 3 weeks or investigators choice chemotherapy. And it worked. Immunotherapy is better than physicians choice chemotherapy in the second-line setting. In fact, not only is it better in response rate, it is better in overall survival, with a hazard ratio of 0.69,' said Bradley Monk...in an interview with Targeted Oncology.'"

Interview

Onvansertib Triplet Shows Promise in KRAS-Mutant Metastatic Colorectal Cancer (Targeted Oncology) - "The preliminary results from the study are interesting because this is a phase Ib dose-escalation trial looking at the standard chemotherapy regimen FOLFIRI plus bevacizumab in combination with onvansertib. What we noticed is that when we looked at some of the correlative work, including capturing circulating tumor DNA (ctDNA), which demonstrated a decrease in percentage ofKRAS-mutated circulating tumor DNA. These were the patients that were treated with the investigational agents in combination with chemotherapy and bevacizumab. Not only did we see evidence of radiographic response, but we also saw evidence of a decrease in theirKRAS-mutated ctDNA."

Interview